Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
Holding ENGN?
Track your performance easily
ENGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.42 - $18.40
Previous CloseN/A
Volume16.79K
Average Volume (3M)125.50K
Market Cap
$364.99M
Enterprise Value$185.82M
Total Cash (Recent Filing)$1.07M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-2.47
Next Earnings
Feb 03, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.50
Shares Outstanding50,976,677
10 Day Avg. Volume69,730
30 Day Avg. Volume125,503
Standard Deviation0.33
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
$24.83Price Target Upside235.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
enGene Holdings News
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe LEGEND study was selected for inclusion in SUO Clinical Trial Consortium (SUO CTC), providing access to U.S./Canadian organization with over 250 trial sites.
Market OpportunityThe market for non-muscle invasive bladder cancer (NMIBC) is expected to expand, driven by effective therapeutics and unmet needs, creating a multi-billion-dollar opportunity.
Product PositioningDetalimogene is promising and will have a role in the treatment landscape, with a niche profile due to its ease of use and lack of special storage requirements compared to Adstiladrin and cretostimogene.
Bears Say
Clinical PerformanceDurability on the efficacy side will be a critical factor for approved products in the treating community, indicating potential challenges for ENGN.
Clinical ProgressClinical progress for detalimogene remains early, and its profile could change materially with more patients.
Commercial ProspectsLimited incremental readthrough to the commercial prospects for detalimogene given the relatively in-line nature of the SUO update.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ENGN FAQ
What was enGene Holdings’s price range in the past 12 months?
enGene Holdings lowest stock price was $4.42 and its highest was $18.40 in the past 12 months.
What is enGene Holdings’s market cap?
enGene Holdings’s market cap is $364.99M.
When is enGene Holdings’s upcoming earnings report date?
enGene Holdings’s upcoming earnings report date is Feb 03, 2025 which is in 3 days.
How were enGene Holdings’s earnings last quarter?
enGene Holdings released its earnings results on Dec 19, 2024. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.396 by $0.046.
Is enGene Holdings overvalued?
According to Wall Street analysts enGene Holdings’s price is currently Undervalued.
Does enGene Holdings pay dividends?
enGene Holdings does not currently pay dividends.
What is enGene Holdings’s EPS estimate?
enGene Holdings’s EPS estimate is -0.38.
How many shares outstanding does enGene Holdings have?
enGene Holdings has 50,976,677 shares outstanding.
What happened to enGene Holdings’s price movement after its last earnings report?
enGene Holdings reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.396. Following the earnings report the stock price went down -2.181%.
Which hedge fund is a major shareholder of enGene Holdings?
Currently, no hedge funds are holding shares in ENGN
---
enGene Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.83 (235.99% Upside)
$24.83 (235.99% Upside)
Blogger Sentiment
Bullish
ENGN Sentiment 100%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 800.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
enGene Holdings
Forbion European Acquisition Corp is a blank check company.
---
ENGN Stock 12 Month Forecast
Average Price Target
$24.83
▲(235.99% Upside)
Technical Analysis
Biogen
―
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ENGN
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-12.64%
reiterated a buy rating 15 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -12.64% per trade.
---